Metabolic profiling of acromegaly using a GC–MS-based nontargeted metabolomic approach
- 24 December 2019
- journal article
- research article
- Published by Springer Nature in Endocrine
- Vol. 67 (2) , 433-441
Abstract
Acromegaly is a rare disease caused by chronic hypersecretion of growth hormone, which leads to multiple comorbidities and reduced life expectancy. The objective of this study was to characterize the serum metabolic profiles of acromegaly patients and identify metabolic biomarkers using metabolomics.Keywords
This publication has 35 references indexed in Scilit:
- Cardiovascular MetabolomicsCirculation Research, 2018
- Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's DiseaseFrontiers in Aging Neuroscience, 2018
- Growth Hormone Research Society perspective on biomarkers of GH action in children and adultsEndocrine Connections, 2018
- Has acromegaly been diagnosed earlier?Journal of Clinical Neuroscience, 2018
- The regulation of the pentose phosphate pathway: Remember KrebsArchives of Biochemistry and Biophysics, 2017
- The development of plasma pseudotargeted GC-MS metabolic profiling and its application in bladder cancerAnalytical and Bioanalytical Chemistry, 2016
- 60 YEARS OF NEUROENDOCRINOLOGY: AcromegalyJournal of Endocrinology, 2015
- Metabolomics-Driven Nutraceutical Evaluation of Diverse Green Tea CultivarsPLOS ONE, 2011
- Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolismPituitary, 2010
- Physiological actions of taurinePhysiological Reviews, 1992